Why the study?
Does spironolactone reduce albuminuria and blood pressure in type 2 diabetic patients with nephropathy?
Does spironolactone reduce albuminuria and blood pressure in type 2 diabetic patients with nephropathy?
Adding spironolactone to maximal ACEi/ARB therapy reduces albuminuria and blood pressure in patients with type 2 diabetes and nephropathy.
Supports spironolactone addition to ACEi/ARB in diabetic nephropathy; extends RCT evidence for additive renoprotection.
Our study suggests that spironolactone safely adds to the reno- and cardiovascular protective benefits of treatment with maximally recommended doses of ACE inhibitor and ARB by reducing albuminuria and blood pressure in type 2 diabetic patients with nephropathy.
No takes yet. Share an insight, caveat, or question.
Rossing et al. (2005) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: